Next Article in Journal
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Next Article in Special Issue
Cytoprotective Effects of Human Platelet Lysate during the Xeno-Free Culture of Human Donor Corneas
Previous Article in Journal
Plant Coumarins with Anti-HIV Activity: Isolation and Mechanisms of Action
Previous Article in Special Issue
Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 3
10.3390/ijms24032841
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Epigenetic Regulation of Corneal Epithelial Differentiation by TET2

by
Yuzuru Sasamoto
1,2,†,
Siyuan Wu
1,2,
Catherine A. A. Lee
1,
Jason Y. Jiang
2,
Bruce R. Ksander
3,
Markus H. Frank
2,4,5,6,‡ and
Natasha Y. Frank
1,4,7,*,‡
1
Division of Genetics, Brigham and Women’s Hospital, Boston, MA 02115, USA
2
Transplant Research Program, Boston Children’s Hospital, Boston, MA 02115, USA
3
Massachusetts Eye & Ear Infirmary, Schepens Eye Research Institute, Boston, MA 02114, USA
4
Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA
5
Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women’s Hospital, Boston, MA 02115, USA
6
School of Medical and Health Sciences, Edith Cowan University, Perth 6027, WA, Australia
7
Department of Medicine, VA Boston Healthcare System, Boston, MA 02132, USA
*
Author to whom correspondence should be addressed.
†
Current Affiliation: Department of Ophthalmology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
‡
Co-senior investigators.
Int. J. Mol. Sci. 2023, 24(3), 2841; https://doi.org/10.3390/ijms24032841
Submission received: 5 November 2022 / Revised: 19 January 2023 / Accepted: 21 January 2023 / Published: 2 February 2023
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Corneal Fibrosis/Scarring and Advances in Therapy)
Browse Figures
Versions Notes

Abstract

:
Epigenetic DNA modification by 5-hydroxymethylcytosine (5hmC), generated by the Ten-eleven translocation (TET) dioxygenases, regulates diverse biological functions in many organ tissues, including the mammalian eye. For example, 5hmC has been shown to be involved in epigenetic regulation of retinal gene expression. However, a functional role of 5hmC in corneal differentiation has not been investigated to date. Here, we examined 5hmC and TET function in the human cornea. We found 5hmC highly expressed in MUC16-positive terminally differentiated cells that also co-expressed the 5hmC-generating enzyme TET2. TET2 knockdown (KD) in cultured corneal epithelial cells led to significant reductions of 5hmC peak distributions and resulted in transcriptional repression of molecular pathways involved in corneal differentiation, as evidenced by downregulation of MUC4, MUC16, and Keratin 12. Additionally, integrated TET2 KD RNA-seq and genome-wide Reduced Representation Hydroxymethylation Profiling revealed novel epigenetically regulated genes expressed by terminally differentiated cells, including KRT78, MYEOV, and MAL. In aggregate, our findings reveal a novel function of TET2 in the epigenetic regulation of corneal epithelial gene expression and identify novel TET2-controlled genes expressed in differentiated corneal epithelial cells. These results point to potential roles for TET2 induction strategies to enhance treatment of corneal diseases associated with abnormal epithelial maturation.

1. Introduction

Corneal epithelial homeostasis is maintained by limbal stem cells (LSCs), which generate transit-amplifying cells migrating centripetally while giving rise to terminally differentiated apical cells [1]. These three main cell populations reside in distinct anatomical niches and can also be recognized by specific marker expression [2]. LSCs located at the basal epithelial layer in the outermost part of the cornea express ABCB5 and p63 [2,3,4,5,6,7,8,9,10]. Transit amplifying cells occupy the basal epithelial layer inside the limbal circle and are characterized by expression of ß-integrin and BCAM [11,12]. Terminally differentiated corneal epithelial cells are found in the apical layers of the central cornea, where they express MUC16 [13]. Despite a relative wealth of knowledge regarding the corneal epithelial hierarchy and transcriptional control of corneal differentiation, the role of epigenetic regulation in corneal gene expression is not well understood.
The significance of epigenetic DNA modifications in eye development and disease has been increasingly recognized over the last decade [14]. DNA methylation at the fifth position of cytosine (5mC) serves as a critical epigenetic modifier of gene expression [15]. Abnormal 5mC levels have been reported in association with aberrant wound healing [16] and Fuchs corneal dystrophy [17]. The Ten-eleven translocation (TET) family of dioxygenases, TET1, TET2, and TET3, modulate DNA methylation patterns through conversion of 5mC to 5-hydroxymethylcytosine (5hmC) [18]. Studies have shown that 5hmC, in addition to being an intermediate of 5mC oxidation, also serves as a stable epigenetic mark with regulatory functions [19]. 5hmC enrichment was reported at genes involved in diverse biological functions, including development, tumorigenesis, stemness, and differentiation [20,21]. However, the role of 5hmC epigenetic modification in corneal differentiation has not been examined to date.
During vertebrate evolution, TET2 diverged from TET1 and TET2 members of the TET family as a result of gene fission, which split the CpG DNA binding CXXC domain into a separate IDAX protein encoded by the CXXC4 gene transcribed in the opposite direction [22]. IDAX, which also serves as an inhibitor of Wnt signaling [23], downregulates TET2 protein expression [22]. In the eye, TET2 was found to play an important role in retinal neurogenesis [24].
Here, we uncover a novel function of TET2 in the regulation of corneal epithelial gene expression through 5hmC modification. In addition, using genome-wide 5hmC profiling correlated with RNA-seq of TET2 KD cells, we identify novel epigenetically regulated genes involved in corneal differentiation.

2. Results

2.1. 5hmC Marks Quiescent Cells in the Limbus

We performed in situ 5mC and 5hmC immunostaining to examine the epigenetic landscape of the human cornea. We found nearly ubiquitous expression of 5mC (Figure 1A). However, 5hmC was mainly detected in ABCB5-positive LSCs located in the basal limbus and in MUC16-positive apical differentiated central corneal cells (Figure 1B). TET1 and TET3 were expressed throughout all corneal layers in the limbus and central cornea (Figure 1C,D). In contrast, TET2 expression was restricted to the MUC16-positive apical differentiated central corneal epithelium (Figure 1E), suggesting a specific function of TET2 in the maintenance of enhanced 5hmC levels during corneal differentiation. Notably, 5hmC-positive cells in the limbus expressed low levels of phosphorylation of serine 10 on histone H3 (H3S10ph) [25] (Figure 1F), pointing to an association of 5hmC expression with cellular quiescence.

2.2. TET2 Regulates the Expression of Corneal Differentiation Genes

To investigate the role of TET2 in corneal epithelial differentiation, we performed TET2 knockdown (KD) in cultured corneal epithelial cells by two distinct siRNAs, designated as TET2 KD#1 and TET2 KD#2 (Figure 2A). Both TET2 KD#1 and TET2 KD#2 led to significant downregulation of the corneal epithelial differentiation markers MUC4, MUC16 [13] and Keratin 12 (KRT12) [26] (Figure 2B). RNA-seq analyses (Figure 3A) identified 344 downregulated and 447 upregulated transcripts shared by both TET2 KD#1 and TET2 KD#2 cultures (Figure 3B, Supplemental Tables S1 and S2). Metascape enrichment analyses of these differentially expressed genes (DEGs) revealed downregulation of terminal differentiation-related pathways such as the apoptotic signaling pathway and the formation of the cornified envelope pathway (Figure 3C), and induction of basal epithelial cell-related pathways such as positive regulation of cell migration and cell–cell adhesion (Figure 3D).

2.3. Identification of Genes Regulated by TET2 through 5hmC Modification

To identify TET2-regulated epigenetic loci, we performed Reduced Representation Hydroxymethylation Profiling (RRHP) of TET2 KD cells compared to controls. We observed a significant reduction of 5hmC site numbers in various exon, intron, and promoter regions (p = 0.0260) (Figure 4A,B). Next, we correlated the changes in gene expression with changes in their respective 5hmC levels (Figure 4C). Overall, we observed 1329 reduced 5hmC peaks in 407 differentially expressed genes in TET2 KD cells (Figure 4C). Metascape analyses of the downregulated genes revealed enrichment of specific pathways involved in Wnt signaling and formation of the cornified envelope. In contrast, upregulated genes were involved in focal adhesion, cell morphogenesis, and positive regulation of cell migration pathways (Figure 4D). Of note, we found that the corneal differentiation markers MUC4 and MUC16 found downregulated in TET2 KD cells also exhibited reduced 5hmC peaks in their exon and intron regions (Table 1).

2.4. Identification of Novel Corneal Differentiation Genes Epigenetically Regulated by TET2

Based on the high TET2 and 5hmC levels in the apical corneal epithelial layers, we hypothesized that TET2 is involved in the epigenetic regulation of genes associated with corneal differentiation. We used cell-surface expressed protein MUC16 to prospectively isolate differentiated corneal epithelial cells [27] and performed RNA-seq analysis of sorted MUC16-positive and MUC16-negative cells isolated from n = 3 human donor corneas to characterize the transcripts associated with corneal differentiation (Figure 5A,B). Next, we compared the genes enriched in MUC16-positive cells to the genes downregulated by TET2 KD (Figure 5C). This comparison identified 13 transcripts, seven of which, i.e., KRT78, MYEOV, MAL, LYPD2, LGALS9C, B4GALT5, and LGALS9, also had reduced 5hmC levels. Since the association of LYPD2, LGALS9C, B4GALT5, and LGALS9 with corneal epithelial differentiation has been reported previously [27,28,29], we focused our further studies on the characterization of KRT78, MYEOV, and MAL. Reduced expression of KRT78, MYEOV, and MAL in TET2 KD cells was validated by RT-PCR and Western blot analyses (Figure 6A and Supplementary Figure S1) and attenuated 5hmC peaks were detected by RRHP in their corresponding genomic regions (Figure 6B). Moreover, we found significant overexpression of KRT78, MYEOV, and MAL, as well as of MUC16 and TET2 transcripts, in sorted MUC16-positive cells by RT-PCR (Figure 6C). In situ KRT78, MYEOV, and MAL protein expression was detected exclusively in the apical corneal epithelial layers, where they co-expressed MUC16 or 5hmC (Figure 6D). Thus, our findings identify KRT78, MYEOV, and MAL as novel epigenetically regulated markers of corneal epithelial differentiation.

3. Discussion

In the current study, we reveal a novel function of TET2 in epigenetic regulation of corneal epithelial gene expression. Using in situ immunofluorescence analyses, RNA-seq and RRHP profiling, we identified TET2-controlled genes expressed by differentiated corneal epithelial cells. Our findings point to a potential role of TET2-inducing strategies for the treatment of corneal diseases associated with abnormal epithelial maturation.
Using in situ immunostaining, we discovered a dichotomy of 5hmC distribution in the human cornea. Increased 5hmC expression was detected in ABCB5-positive LSCs and MUC16-positive terminally differentiated cells, while the majority of transit amplifying and differentiating MUC16-negative cells exhibited low 5hmC levels. These findings are in line with previous observations of high 5hmC levels in stem cells such as embryonic stem cells (ESCs) [30,31] and hematopoietic stem cells [32] and in terminally differentiated cells such as differentiated epithelial cells [33], but reduced 5hmC levels in proliferative cells such as basal cells in the small intestine, the skin epithelium [33], and in neural progenitor cells [34]. High 5hmC levels observed upon differentiation are thought to be associated with a “poised” chromatin configuration, which activates transcription in response to environmental stimuli, whereas in undifferentiated ESCs high 5hmC levels are correlated with transcriptional repression regulated by TET1 [31].
In our study of the cornea, we observed high TET1, TET3, and 5hmC levels in ABCB5-positive LSCs, which could relate to their undifferentiated stem cell phenotype. While we also detected continuing TET1 and TET3 expression in early and late transit amplifying cells and differentiating suprabasal cells, their 5hmC levels were low or undetectable. This finding can be explained by continuing oxidation of the 5hmC by TET1 and TET3 in these cells and their proliferation. TET2 was specifically localized to terminally differentiated MUC16-positive cells where it was co-expressed with 5hmC. Intriguingly, while TET2 KD led to significant reduction of 5hmC peaks, it was associated with transcriptional repression of pathways involved in corneal differentiation along with activation of basal epithelial cell-related pathways such as positive regulation of cell migration and cell-cell adhesion. Additional future studies at the single cell level might serve to further dissect such divergent effects of TETs on epigenetic regulation of gene expression in the cornea.
Consistent with the essential role of TET2 in corneal epithelial differentiation, TET2 KD was associated with significant downregulation of distinct pathways involved in Wnt signaling and in the formation of the cornified envelope, with corresponding reduction of 5hmC levels. TET2 KD hereby reduced expression of the established corneal differentiation markers MUC4, MUC16, and KRT12. Furthermore, integration of TET2 KD RNA-seq and genome-wide 5hmC analyses revealed additional epigenetically regulated corneal differentiation genes, 13 of which were also highly expressed in MUC16-positive cells. Three of those genes, i.e., KRT78, MYEOV, and MAL, had not previously been specifically described in the cornea. Our flow cytometry and immunostaining analyses now demonstrate, for the first time, their high expression among apical differentiated corneal epithelial cells, suggesting a potential role of these genes in corneal epithelial formation.
Corneal epithelial maturation plays a critical role in the formation of the intact and clear ocular surface. Abnormal corneal epithelial differentiation has been observed in several ocular surface diseases, including dry eye disease [35], diabetes mellitus-related compromised barrier function [36], and enhanced epithelial fragility [37]. The cornea barrier function is highly dependent on the formation of tight epithelial junctions, as well as mucins, which protect the cornea from external allergens and pathogens [38,39]. Therefore, our findings implicating TET2 in epigenetic regulation of corneal epithelial gene expression point to potential therapeutic roles for TET2-inducing approaches for the treatment of ocular surface diseases.
In sum, our study reveals an essential novel role of TET2 in epigenetic control of corneal epithelial differentiation and discovers novel epigenetically regulated genes expressed by terminally differentiated cells. Therefore, our results raise the possibility of therapeutic potential of TET2-inducing therapies for the treatment of eye diseases associated with abnormal epithelial maturation.

4. Methods

4.1. Human Tissues

Human whole globes and corneal tissues were obtained from the Saving Sight eye bank, Kansas City, MO, and the CorneaGen eye bank, Seattle, WA, under Institutional Review Board (IRB)-approved protocols.

4.2. Tissue Processing

For immunostaining, whole eye globes were processed as follows: One group was fixed with 10% neutral buffered formalin (Fisher Scientific, Pittsburgh, PA, USA) at 4 °C overnight and submerged into 70% ethanol. Subsequently, the tissues were paraffin-embedded at the Brigham and Women’s Hospital’s (BWH) Pathology Core. Another group was embedded in TissueTek® O.C.T Compound (Sakura, Tokyo, Japan) and kept frozen at −80 °C. For cell culture and flow cytometry, 8mm diameter central cornea sections were separated from the remaining corneal tissues by a disposable biopsy punch (Integra LifeSciences, Plainsboro, NJ, USA). After the mechanical removal of corneal endothelial cells, limbal and central corneal tissues were incubated with PluriSTEM Dispase II Solution (MilliporeSigma, Burlington, MA, USA) at 37 °C for 1 h. Limbal and central corneal epithelial cells were scraped and incubated with TrypLE Express Enzyme (Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C for 30 min. For corneal epithelial cell culture, dissociated limbal epithelial cells were maintained in DMEM/F12 medium (Thermo Fisher Scientific) supplemented with 10 ng/mL keratinocyte growth factor (KGF) (PeproTech, Rocky Hill, NJ, USA), 10 μM Y-27632 (Tocris Bioscience, Bristol, UK) and B-27 Supplement (Thermo Fisher Scientific) [40].

4.3. Immunostaining

Formalin-fixed paraffin-embedded sections were subjected to deparaffinization and antigen retrieval steps before immunostaining as described [12]. The tissue sections were permeabilized with Triton-X (MilliporeSigma) containing buffer and blocked with 5–10% normal donkey or goat serum (Jackson ImmunoResearch Laboratories, West Grove, PA) or 1% bovine serum albumin (BSA) (MilliporeSigma) containing buffer. The fresh frozen sections were denatured with 2N-HCl (VWR, Radnor, PA, USA) at room temperature for 15 min and incubated with 100 mM Tris-HCl (pH 8.0) (Boston BioProducts, Milford, MA, USA) at room temperature for 10 min before blocking. Blocked sections were incubated with primary antibodies at 4 °C overnight. Primary antibodies used in the study were mouse anti-5mC polyclonal antibody (pAb) (1:5000, Active Motif, Carlsbad, CA, USA), rabbit anti-5hmC pAb (1:5000, Active Motif), mouse anti-ABCB5 monoclonal antibody (mAb) (clone 3C2-1D12) (10 μg/mL, [41]), mouse anti-MUC16 mAb (1:400, Abcam, Cambridge, UK), mouse anti-TET1 mAb (1:200, GeneTex, Irvine, CA, USA), rabbit anti-TET2 pAb (1:200, GeneTex), rabbit anti-TET3 pAb (1:400, GeneTex), mouse anti-H3S10ph mAb (1:250, GeneTex), rabbit anti-KRT78 pAb (1:200, MyBiosource, San Diego, CA, USA), rabbit anti-MYEOV pAb (1:100, Atlas Antibodies, Bromma, Sweden), and mouse anti-MAL mAb (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Sections were incubated with Alexa fluor 488 or 568-conjugated secondary antibodies (1:400, Abcam) at room temperature for 1 h and with Hoechst 33342 (1:400, Thermo Fisher Scientific) at room temperature for 10 min. The image capture was performed using a C2+ confocal microscope (Nikon, Tokyo, Japan) and analyses were performed using NIS-Elements AR v4.30.01 (Nikon).

4.4. RNA Interference

Gene knockdown (KD) experiments were performed as reported previously [12,42]. Briefly, transfection of cultured corneal epithelial cells was performed using Lipofectamine™ RNAiMAX Transfection Reagent (Thermo Fisher Scientific). SilencerTM Select siRNAs (Thermo Fisher Scientific) used were Silencer™ Select Negative Control No.1 siRNA and TET2 siRNAs (TET2 KD#1 [s29441] and TET2 KD#2 [s29442]). siRNAs were transfected on days 0, 2, and 4 and the cells were harvested on day 7.

4.5. Western Blot

Cell lysis and protein extraction were performed using RIPA buffer (Cell Signaling Technology, Danvers, MA, USA) supplemented with cOmplete™ Protease Inhibitor Cocktail (MilliporeSigma). The lysates were mixed with SDS-sample buffer (Boston BioProducts) and 2-mercaptoethanol (MilliporeSigma) and denatured at 95 °C for 10 min. The proteins separated by SDS-PAGE gel electrophoresis (Bio-rad, Hercules, CA, USA) were transferred onto PVDF blotting membranes (GE Healthcare Life Sciences, Marlborough, MA, USA). After blocking with 5% blotting-grade blocker (Bio-Rad) containing buffer at room temperature for 1 h, the membranes were incubated with primary antibodies diluted in 2.5% blocking buffer at 4 °C overnight. Primary antibodies used were rabbit anti-β-actin pAb (1:1000, Cell Signaling Technology), rabbit anti-TET2 pAb (1:2000, GeneTex), rabbit anti-MUC4 pAb (1:1000, Abcam), rabbit anti-MUC16 mAb (1:10,000, Abcam), rabbit anti-KRT12 mAb (1:5000, Abcam), rabbit anti-KRT78 pAb (1:500, MyBiosource), and rabbit anti-MYEOV pAb (1:1000, MyBiosource). The membranes were subsequently incubated with HRP-conjugated secondary antibodies (1:1000, Cell Signaling Technology) at room temperature for 1 h and signals were developed by Western Lightning Plus-ECL (PerkinElmer, Waltham, MA, USA) or SuperSignalTM West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific). The images were acquired using the ChemiDoc MP Imaging System (Bio-Rad). Relative protein expression levels against β-actin expression were calculated using Image Lab software v5.2.1 (Bio-Rad).

4.6. RNA-Seq

Total RNA was extracted either by AllPrep DNA/RNA Mini Kit (QIAGEN, Hilden, Germany) or RNeasy Plus Mini Kit (QIAGEN). After the removal of contaminating genomic DNA by a DNA-free™ DNA Removal Kit (Thermo Fisher Scientific), mRNA libraries were generated by SMART-Seq® v4 Ultra® Low Input RNA Kit for Sequencing (Clontech, Mountain View, CA, USA). Sequencing was carried out by the Illumina NextSeq 500 Platform (Single-end 75 bp) (Illumina, San Diego, CA, USA) at the Molecular Biology Core Facility (MBCF) of the Dana–Farber Cancer Institute. RNA-seq counts were generated by Salmon [43]. Differential gene expression (DEG) analyses were performed using DESeq2 [44]. DEGs with adjusted p values < 0.05 were used for further analyses. The pathway enrichment in DEGs was determined using the Metascape software (http://metascape.org, accessed on 14 February 2022) [45]. DEGs are listed in Supplementary Tables S1 and S2 for TET2 KD and Supplementary Tables S5 and S6 for MUC16-positive vs. MUC16-negative.

4.7. Genome-Wide 5hmC Analysis

Genomic DNA was extracted using an AllPrep DNA/RNA Mini Kit (QIAGEN). Genome-wide 5hmC analysis (Reduced Representation Hydroxymethylation Profiling: RRHP) was performed by Zymo Research (Irvine, CA, USA) [46]. The 5hmC enrichment data from the control sample were compared against TET2 knockdown samples. Read data from the top (“+”) and bottom (“−”) strands were considered separately to account for asymmetric 5hmC modification along a CpG palindrome of double-stranded DNA. A log2 fold change was computed for each comparison. The following criteria were applied to define differential 5hmC peaks: at least one sample must have coverage > 4 and at least one comparison must show log2 fold change > 1. Genes that were differentially expressed at the RNA level and differentially enriched at the 5hmC level were compiled. For each siRNA condition (TET2 KD#1 and TET2 KD#2) and each gene region (exon, intron, and promoter), RNA-seq log2 fold change was plotted on the x-axis against 5hmC log2 fold change on the y-axis. Complete RRHP data are available in Supplementary Tables S3 and S4.

4.8. Quantitative Reverse Transcription PCR (qRT-PCR)

Total RNA was extracted using either an AllPrep DNA/RNA Mini Kit or an RNeasy Plus Mini Kit (QIAGEN). After the removal of contaminating genomic DNA by a DNA-free™ DNA Removal Kit (Thermo Fisher Scientific) from extracted RNA, cDNA synthesis was performed using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). qPCR was conducted with TaqManTM Gene Expression Assay probes (Thermo Fisher Scientific) and TaqManTM Fast Universal PCR Master Mix (Thermo Fisher Scientific). The TaqManTM probes used were GAPDH (Hs99999905_m1), KRT78 (Hs00542779_m1), MYEOV (Hs00371084_m1), MAL (Hs00242748_m1), MUC16 (Hs01065175_m1), and TET2 (Hs00325999_m1). The PCR cycling condition was 95 °C for 20 s and 50 cycles of [95 °C/1 s; 60 °C/20 s] using a StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific). Calculation of ΔΔCt values was performed using GAPDH as a reference gene.

4.9. Flow Cytometric Analyses

Dissociated central corneal epithelial cells were stained with 1.0 μg/mL mouse anti-MUC16 mAb (Abcam) conjugated with Alexa Fluor 647 (Thermo Fisher Scientific) on ice for 30 min. 0.125 µg/mL PE-conjugated anti-CD45 mAb (clone 2D1, BioLegend, San Diego, CA, USA) was used to remove any contaminating hematopoietic cells and a 30nM SYTOX Green Nucleic Acid Stain solution (Thermo Fisher Scientific) was used for dead-cell staining. The top 5% of MUC16-positive cells and the bottom 30% of MUC16-negative cells were isolated using a FACSAria II cell sorter (BD Biosciences, San Jose, CA, USA). The data were analyzed using FlowJo (BD Biosciences) software.

4.10. Statistical Analysis

Paired t-tests were performed to compare two groups and Dunnett’s multiple comparisons tests were performed to compare experimental groups against a control group using the Prism 8 software (GraphPad Software, San Diego, CA, USA). The data are presented as mean ± standard deviation (SD) values derived from five or more independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24032841/s1.

Author Contributions

Y.S., M.H.F. and N.Y.F. designed the study; Y.S., S.W., M.H.F. and N.Y.F. wrote the manuscript; Y.S., S.W., C.A.A.L., J.Y.J., M.H.F. and N.Y.F. performed experiments and analyzed and compiled the data; Y.S., B.R.K., M.H.F. and N.Y.F. performed data interpretation. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by NIH/NEI grant 1K99EY031741 to Y.S., NIH/NEI grants 1R01EY025794 and R24EY028767 and NIH/NIA grant 1P01AG071463-01A1 to N.Y.F., B.R.K and M.H.F, NIH/NHLBI grant 1R01HL161087 to N.Y.F. and M.H.F., NIH/NEI Schepens Core grant P30EY003790 to B.R.K., an Alcon Young Investigator Grant and a Japan Eye Bank Association Overseas Award to Y.S., and a VA R&D Merit Review Award (1I01RX000989) and a Harvard Stem Cell Institute seed grant award to N.Y.F.

Institutional Review Board Statement

Human donor tissues were obtained according to Institutional Review Board (IRB)-approved protocols.

Data Availability Statement

The RNA-seq data were deposited to the Gene Expression Omnibus under accession number GSE216213.

Acknowledgments

We would like to thank the corneal donor patients. We thank the BWH Pathology Core and the DFCI Flow Cytometry Core, as well as the DFCI Molecular Biology Core Facilities and the Harvard School of Public Health Bioinformatics Core.

Conflicts of Interest

M.H.F., B.R.K. and N.Y.F. are inventors or co-inventors of US and international patents assigned to Brigham and Women’s Hospital, Boston Children’s Hospital, the Massachusetts Eye and Ear Infirmary, and/or the VA Boston Healthcare System, Boston, MA, licensed to Ticeba GmbH (Heidelberg, Germany) and Rheacell GmbH & Co. KG (Heidelberg, Germany). M.H.F. serves as a scientific advisor to and holds stock in Ticeba GmbH and Rheacell GmbH & Co. KG.

References

  1. Thoft, R.A.; Friend, J. The X, Y, Z hypothesis of corneal epithelial maintenance. Investig. Ophthalmol. Vis. Sci. 1983, 24, 1442–1443. [Google Scholar]
  2. Gonzalez, G.; Sasamoto, Y.; Ksander, B.R.; Frank, M.H.; Frank, N.Y. Limbal stem cells: Identity, developmental origin, and therapeutic potential. Wiley Interdiscip. Rev. Dev. Biol. 2018, 7, e303. [Google Scholar] [CrossRef] [PubMed]
  3. Jongkhajornpong, P.; Nakamura, T.; Sotozono, C.; Nagata, M.; Inatomi, T.; Kinoshita, S. Elevated expression of ABCB5 in ocular surface squamous neoplasia. Sci. Rep. 2016, 6, 20541. [Google Scholar] [CrossRef]
  4. Kureshi, A.K.; Dziasko, M.; Funderburgh, J.L.; Daniels, J.T. Human corneal stromal stem cells support limbal epithelial cells cultured on RAFT tissue equivalents. Sci. Rep. 2015, 5, 16186. [Google Scholar] [CrossRef] [PubMed]
  5. Mathan, J.J.; Ismail, S.; McGhee, J.J.; McGhee, C.N.; Sherwin, T. Sphere-forming cells from peripheral cornea demonstrate the ability to repopulate the ocular surface. Stem. Cell Res. Ther. 2016, 7, 81. [Google Scholar] [CrossRef]
  6. Norrick, A.; Esterlechner, J.; Niebergall-Roth, E.; Dehio, U.; Sadeghi, S.; Schröder, H.M.; Ballikaya, S.; Stemler, N.; Ganss, C.; Dieter, K.; et al. Process development and safety evaluation of ABCB5(+) limbal stem cells as advanced-therapy medicinal product to treat limbal stem cell deficiency. Stem. Cell Res. Ther. 2021, 12, 194. [Google Scholar] [CrossRef] [PubMed]
  7. Parfitt, G.J.; Kavianpour, B.; Wu, K.L.; Xie, Y.; Brown, D.J.; Jester, J.V. Immunofluorescence Tomography of Mouse Ocular Surface Epithelial Stem Cells and Their Niche Microenvironment. Investig. Ophthalmol. Vis. Sci. 2015, 56, 7338–7344. [Google Scholar] [CrossRef]
  8. Shaharuddin, B.; Ahmad, S.; Md Latar, N.; Ali, S.; Meeson, A. A Human Corneal Epithelial Cell Line Model for Limbal Stem Cell Biology and Limbal Immunobiology. Stem. Cells Transl. Med. 2017, 6, 761–766. [Google Scholar] [CrossRef]
  9. Shaharuddin, B.; Osei-Bempong, C.; Ahmad, S.; Rooney, P.; Ali, S.; Oldershaw, R.; Meeson, A. Human limbal mesenchymal stem cells express ABCB5 and can grow on amniotic membrane. Regen. Med. 2016, 11, 273–286. [Google Scholar] [CrossRef]
  10. Pellegrini, G.; Dellambra, E.; Golisano, O.; Martinelli, E.; Fantozzi, I.; Bondanza, S.; Ponzin, D.; McKeon, F.; De Luca, M. p63 identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. USA 2001, 98, 3156–3161. [Google Scholar] [CrossRef]
  11. Hayashi, R.; Ishikawa, Y.; Sasamoto, Y.; Katori, R.; Nomura, N.; Ichikawa, T.; Araki, S.; Soma, T.; Kawasaki, S.; Sekiguchi, K.; et al. Co-ordinated ocular development from human iPS cells and recovery of corneal function. Nature 2016, 531, 376–380. [Google Scholar] [CrossRef] [PubMed]
  12. Sasamoto, Y.; Lee, C.A.; Wilson, B.J.; Buerger, F.; Martin, G.; Mishra, A.; Kiritoshi, S.; Tran, J.; Gonzalez, G.; Hildebrandt, F.; et al. Limbal BCAM expression identifies a proliferative progenitor population capable of holoclone formation and corneal differentiation. Cell Rep. 2022, 40, 111166. [Google Scholar] [CrossRef] [PubMed]
  13. Gipson, I.K.; Argueso, P. Role of mucins in the function of the corneal and conjunctival epithelia. Int. Rev. Cytol. 2003, 231, 1–49. [Google Scholar]
  14. Chen, E.; Bohm, K.; Rosenblatt, M.; Kang, K. Epigenetic regulation of anterior segment diseases and potential therapeutics. Ocul. Surf. 2020, 18, 383–395. [Google Scholar] [CrossRef] [PubMed]
  15. He, B.; Zhang, C.; Zhang, X.; Fan, Y.; Zeng, H.; Liu, J.; Meng, H.; Bai, D.; Peng, J.; Zhang, Q.; et al. Tissue-specific 5-hydroxymethylcytosine landscape of the human genome. Nat. Commun. 2021, 12, 4249. [Google Scholar] [CrossRef]
  16. Luo, G.; Jing, X.; Yang, S.; Peng, D.; Dong, J.; Li, L.; Reinach, P.S.; Yan, D. DNA Methylation Regulates Corneal Epithelial Wound Healing by Targeting miR-200a and CDKN2B. Investig. Ophthalmol. Vis. Sci. 2019, 60, 650–660. [Google Scholar] [CrossRef]
  17. Khuc, E.; Bainer, R.; Wolf, M.; Clay, S.M.; Weisenberger, D.J.; Kemmer, J.; Weaver, V.M.; Hwang, D.G.; Chan, M.F. Comprehensive characterization of DNA methylation changes in Fuchs endothelial corneal dystrophy. PLoS ONE 2017, 12, e0175112. [Google Scholar] [CrossRef]
  18. Shen, L.; Wu, H.; Diep, D.; Yamaguchi, S.; D’Alessio, A.C.; Fung, H.L.; Zhang, K.; Zhang, Y. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 2013, 153, 692–706. [Google Scholar] [CrossRef] [PubMed]
  19. Bachman, M.; Uribe-Lewis, S.; Yang, X.; Williams, M.; Murrell, A.; Balasubramanian, S. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat. Chem. 2014, 6, 1049–1055. [Google Scholar] [CrossRef]
  20. Lian, C.G.; Xu, Y.; Ceol, C.; Wu, F.; Larson, A.; Dresser, K.; Xu, W.; Tan, L.; Hu, Y.; Zhan, Q.; et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150, 1135–1146. [Google Scholar] [CrossRef]
  21. Shi, D.Q.; Ali, I.; Tang, J.; Yang, W.C. New Insights into 5hmC DNA Modification: Generation, Distribution and Function. Front. Genet. 2017, 8, 100. [Google Scholar] [CrossRef] [PubMed]
  22. Ko, M.; An, J.; Bandukwala, H.S.; Chavez, L.; Aijo, T.; Pastor, W.A.; Segal, M.F.; Li, H.; Koh, K.P.; Lähdesmäki, H.; et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 2013, 497, 122–126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Hino, S.-I.; Kishida, S.; Michiue, T.; Fukui, A.; Sakamoto, I.; Takada, S.; Asashima, M.; Kikuchi, A. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol. Cell Biol. 2001, 21, 330–342. [Google Scholar] [CrossRef] [PubMed]
  24. Seritrakul, P.; Gross, J.M. Tet-mediated DNA hydroxymethylation regulates retinal neurogenesis by modulating cell-extrinsic signaling pathways. PLoS Genet. 2017, 13, e1006987. [Google Scholar] [CrossRef]
  25. Prigent, C.; Dimitrov, S. Phosphorylation of serine 10 in histone H3, what for? J. Cell Sci. 2003, 116, 3677–3685. [Google Scholar] [CrossRef]
  26. Sun, T.-T.; Tseng, S.C.G.; Huang, A.J.-W.; Cooper, D.; Schermer, A.; Kavanaugh-Lynch, M.; Weiss, R.; Eichner, R. Monoclonal antibody studies of mammalian epithelial keratins: A review. Ann. N. Y. Acad Sci. 1985, 455, 307–329. [Google Scholar] [CrossRef]
  27. Collin, J.; Queen, R.; Zerti, D.; Bojic, S.; Dorgau, B.; Moyse, N.; Molina, M.M.; Yang, C.; Dey, S.; Reynolds, G.; et al. A single cell atlas of human cornea that defines its development, limbal progenitor cells and their interactions with the immune cells. Ocul. Surf. 2021, 21, 279–298. [Google Scholar] [CrossRef]
  28. Shimmura-Tomita, M.; Wang, M.; Taniguchi, H.; Akiba, H.; Yagita, H.; Hori, J. Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts. PLoS ONE 2013, 8, e63620. [Google Scholar] [CrossRef]
  29. Kitayama, K.; Hayashida, Y.; Nishida, K.; Akama, T.O. Enzymes responsible for synthesis of corneal keratan sulfate glycosaminoglycans. J. Biol. Chem. 2007, 282, 30085–30096. [Google Scholar] [CrossRef]
  30. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324, 930–935. [Google Scholar] [CrossRef]
  31. Pastor, W.A.; Pape, U.J.; Huang, Y.; Henderson, H.R.; Lister, R.; Ko, M.; McLoughlin, E.M.; Brudno, Y.; Mahapatra, S.; Kapranov, P.; et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011, 473, 394–397. [Google Scholar] [CrossRef] [PubMed]
  32. Moran-Crusio, K.; Reavie, L.; Shih, A.; Abdel-Wahab, O.; Ndiaye-Lobry, D.; Lobry, C.; Figueroa, M.E.; Vasanthakumar, A.; Patel, J.; Zhao, X.; et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20, 11–24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Haffner, M.C.; Chaux, A.; Meeker, A.K.; Esopi, D.M.; Gerber, J.; Pellakuru, L.G.; Toubaji, A.; Argani, P.; Iacobuzio-Donahue, C.; Nelson, W.G.; et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2, 627–637. [Google Scholar] [CrossRef] [PubMed]
  34. Hahn, M.A.; Qiu, R.; Wu, X.; Li, A.X.; Zhang, H.; Wang, J.; Jui, J.; Jin, S.-G.; Jiang, Y.; Pfeifer, G.P.; et al. Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis. Cell Rep. 2013, 3, 291–300. [Google Scholar] [CrossRef] [PubMed]
  35. Argueso, P.; Spurr-Michaud, S.; Russo, C.L.; Tisdale, A.; Gipson, I.K. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Investig. Ophthalmol. Vis. Sci. 2003, 44, 2487–2495. [Google Scholar] [CrossRef] [PubMed]
  36. Chen, W.-L.; Lin, C.-T.; Ko, P.-S.; Yeh, P.-T.; Kuan, Y.-H.; Hu, F.-R.; Yang, C.-M. In vivo confocal microscopic findings of corneal wound healing after corneal epithelial debridement in diabetic vitrectomy. Ophthalmology 2009, 116, 1038–1047. [Google Scholar] [CrossRef]
  37. Saini, J.S.; Khandalavla, B. Corneal epithelial fragility in diabetes mellitus. Can. J. Ophthalmol. 1995, 30, 142–146. [Google Scholar] [PubMed]
  38. Hodges, R.R.; Dartt, D.A. Tear film mucins: Front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins. Exp. Eye Res. 2013, 117, 62–78. [Google Scholar] [CrossRef]
  39. Mantelli, F.; Argueso, P. Functions of ocular surface mucins in health and disease. Curr. Opin. Allergy Clin. Immunol. 2008, 8, 477–483. [Google Scholar] [CrossRef]
  40. Miyashita, H.; Yokoo, S.; Yoshida, S.; Kawakita, T.; Yamagami, S.; Tsubota, K.; Shimmura, S. Long-term maintenance of limbal epithelial progenitor cells using rho kinase inhibitor and keratinocyte growth factor. Stem. Cells Transl. Med. 2013, 2, 758–765. [Google Scholar] [CrossRef]
  41. Ksander, B.R.; Kolovou, P.E.; Wilson, B.J.; Saab, K.R.; Guo, Q.; Ma, J.; McGuire, S.P.; Gregory, M.S.; Vincent, W.J.B.; Perez, V.L.; et al. ABCB5 is a limbal stem cell gene required for corneal development and repair. Nature 2014, 511, 353–357. [Google Scholar] [CrossRef] [PubMed]
  42. Fujimoto, S.; Hayashi, R.; Hara, S.; Sasamoto, Y.; Harrington, J.; Tsujikawa, M.; Nishida, K. KLF4 prevents epithelial to mesenchymal transition in human corneal epithelial cells via endogenous TGF-beta2 suppression. Regen. Ther. 2019, 11, 249–257. [Google Scholar] [CrossRef] [PubMed]
  43. Patro, R.; Duggal, G.; Love, M.I.; Irizarry, R.A.; Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods. 2017, 14, 417–419. [Google Scholar] [CrossRef] [PubMed]
  44. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014, 15, 550. [Google Scholar] [CrossRef] [PubMed]
  45. Zhou, Y.; Zhou, B.; Pache, L.; Chang, M.; Khodabakhshi, A.H.; Tanaseichuk, O.; Benner, C.; Chanda, S.K. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 2019, 10, 1523. [Google Scholar] [CrossRef] [PubMed]
  46. Petterson, A.; Chung, T.H.; Tan, D.; Sun, X.; Jia, X.Y. RRHP: A tag-based approach for 5-hydroxymethylcytosine mapping at single-site resolution. Genome Biol. 2014, 15, 456. [Google Scholar] [CrossRef]
Ijms 24 02841 g001 550
Figure 1. Characterization of 5mC and 5hmC expression in the human cornea. Representative immunostaining analyses of: (A) 5mC expression in the limbus (top) and central cornea (bottom), (B) ABCB5 and 5hmC co-expression in the limbus (top), and MUC16 and 5hmC co-expression in the central cornea (bottom), (C) TET1 and 5hmC co-staining in the limbus (top) and central cornea (bottom), (D) Co-expression of ABCB5 and TET3 in the limbus (top), and co-staining of MUC16 and TET3 in the central cornea (bottom), (E) ABCB5 and TET2 co-staining in the limbus (top), and MUC16 and TET2 co-expression in the central cornea (bottom), (F) Co-staining of H3S10ph and 5hmC in the limbus (top) and the central cornea (bottom). Nuclei stained with Hoechst 33342 (blue), n = 3. Scale bar, 20 µm.
Figure 1. Characterization of 5mC and 5hmC expression in the human cornea. Representative immunostaining analyses of: (A) 5mC expression in the limbus (top) and central cornea (bottom), (B) ABCB5 and 5hmC co-expression in the limbus (top), and MUC16 and 5hmC co-expression in the central cornea (bottom), (C) TET1 and 5hmC co-staining in the limbus (top) and central cornea (bottom), (D) Co-expression of ABCB5 and TET3 in the limbus (top), and co-staining of MUC16 and TET3 in the central cornea (bottom), (E) ABCB5 and TET2 co-staining in the limbus (top), and MUC16 and TET2 co-expression in the central cornea (bottom), (F) Co-staining of H3S10ph and 5hmC in the limbus (top) and the central cornea (bottom). Nuclei stained with Hoechst 33342 (blue), n = 3. Scale bar, 20 µm.
Ijms 24 02841 g001
Ijms 24 02841 g002 550
Figure 2. Expression of corneal differentiation genes in TET2 KD cultured corneal epithelial cells. (A) Left, Western blot analyses of TET2 protein expression in TET2 KD cells. Right, bar graphs represent the quantitative analyses of TET2 protein expression (TET2 KD#1: 21.6 ± 7.2%, TET2 ± KD#2: 5.8 ± 4.7%, n = 5; **** p < 0.0001). Data were analyzed using a Tukey’s multiple comparisons test. (B) Top, Western blot analyses of MUC4, MUC16 and KRT12 expression in TET2 KD cells. Bottom, bar graphs represent the quantitative analyses of expressions of MUC4, MUC16, and KRT12 protein (TET2 KD#1: 31.3 ± 24.7%, TET2 ± KD#2: 25.1 ± 13.9% for MUC4, TET2 KD#1: 47.5 ± 19.0%, TET2 ± KD#2: 14.3 ± 7.3% for MUC16, TET2 KD#1: 38.8 ± 29.5%, TET2 ± KD#2: 7.0 ± 6.0% for KRT12; n = 5, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001). Data were analyzed using a Tukey’s multiple comparisons test.
Figure 2. Expression of corneal differentiation genes in TET2 KD cultured corneal epithelial cells. (A) Left, Western blot analyses of TET2 protein expression in TET2 KD cells. Right, bar graphs represent the quantitative analyses of TET2 protein expression (TET2 KD#1: 21.6 ± 7.2%, TET2 ± KD#2: 5.8 ± 4.7%, n = 5; **** p < 0.0001). Data were analyzed using a Tukey’s multiple comparisons test. (B) Top, Western blot analyses of MUC4, MUC16 and KRT12 expression in TET2 KD cells. Bottom, bar graphs represent the quantitative analyses of expressions of MUC4, MUC16, and KRT12 protein (TET2 KD#1: 31.3 ± 24.7%, TET2 ± KD#2: 25.1 ± 13.9% for MUC4, TET2 KD#1: 47.5 ± 19.0%, TET2 ± KD#2: 14.3 ± 7.3% for MUC16, TET2 KD#1: 38.8 ± 29.5%, TET2 ± KD#2: 7.0 ± 6.0% for KRT12; n = 5, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001). Data were analyzed using a Tukey’s multiple comparisons test.
Ijms 24 02841 g002
Ijms 24 02841 g003 550
Figure 3. Characterization of TET2-regulated pathways in corneal epithelial cells. (A) Volcano plots depicting mRNA expression levels in TET2 KD#1 (left) and TET2 KD#2 (right) cultures. Blue dots represent differentially expressed genes (DEGs) selected as described in the methods. TET2 expression is depicted with red dots. (B) Venn diagrams of the overlapping downregulated genes (left) and upregulated genes (right) in TET2 KD#1 and TET2 KD#2 cultures. Metascape enrichment analysis of the downregulated (C) and upregulated (D) DEGs shared by both TET2 KD#1 and TET2 KD#2 cultures. All experiments were repeated n = 3 times.
Figure 3. Characterization of TET2-regulated pathways in corneal epithelial cells. (A) Volcano plots depicting mRNA expression levels in TET2 KD#1 (left) and TET2 KD#2 (right) cultures. Blue dots represent differentially expressed genes (DEGs) selected as described in the methods. TET2 expression is depicted with red dots. (B) Venn diagrams of the overlapping downregulated genes (left) and upregulated genes (right) in TET2 KD#1 and TET2 KD#2 cultures. Metascape enrichment analysis of the downregulated (C) and upregulated (D) DEGs shared by both TET2 KD#1 and TET2 KD#2 cultures. All experiments were repeated n = 3 times.
Ijms 24 02841 g003
Ijms 24 02841 g004 550
Figure 4. Identification of epigenetically regulated pathways through integration of RNA-seq and Reduced Representation Hydroxymethylation Profiling (RRHP) analyses of TET2 KD cells. (A) Scatter plots of 5hmC enrichment in TET2 KD#1 (left) and TET2 KD#2 (right) cultures. (B) Bar graphs represent the distribution of 5hmC site numbers in exon, intron, and promoter regions. (C) Scatter plots depict the correlation between the DEGs (x-axis) and corresponding differentially enriched 5hmC levels (y-axis) shared between TET2 KD#1 and TET2 KD#2 cultures selected as described in methods. (D) Metascape enrichment analysis of the downregulated (top) and upregulated (bottom) DEGs with reduced 5hmC levels.
Figure 4. Identification of epigenetically regulated pathways through integration of RNA-seq and Reduced Representation Hydroxymethylation Profiling (RRHP) analyses of TET2 KD cells. (A) Scatter plots of 5hmC enrichment in TET2 KD#1 (left) and TET2 KD#2 (right) cultures. (B) Bar graphs represent the distribution of 5hmC site numbers in exon, intron, and promoter regions. (C) Scatter plots depict the correlation between the DEGs (x-axis) and corresponding differentially enriched 5hmC levels (y-axis) shared between TET2 KD#1 and TET2 KD#2 cultures selected as described in methods. (D) Metascape enrichment analysis of the downregulated (top) and upregulated (bottom) DEGs with reduced 5hmC levels.
Ijms 24 02841 g004
Ijms 24 02841 g005 550
Figure 5. Identification of TET2-regulated genes enriched in differentiated corneal cells. (A) Representative flow cytometry analyses of MUC16 expression in central corneal epithelial cells. SSC, side scatter; H, height: AF647, Alexa Fluor 647. (B) Volcano plot depicting DEGs between flow cytometrically sorted MUC16-positive and MUC16-negative cells. Orange dots depict the genes enriched in MUC16-negative cells. Purple dots represent the genes enriched in MUC16-positive cells. Genes were selected as described in the methods. (C) Left, Venn diagram of the genes upregulated in MUC16-positive cells and the downregulated genes in TET2 KD cells. Right, the table shows the list of 13 overlapping genes. KRT78, MAL, and MYEOV highlighted in red were selected for functional analyses, as described in Figure 6.
Figure 5. Identification of TET2-regulated genes enriched in differentiated corneal cells. (A) Representative flow cytometry analyses of MUC16 expression in central corneal epithelial cells. SSC, side scatter; H, height: AF647, Alexa Fluor 647. (B) Volcano plot depicting DEGs between flow cytometrically sorted MUC16-positive and MUC16-negative cells. Orange dots depict the genes enriched in MUC16-negative cells. Purple dots represent the genes enriched in MUC16-positive cells. Genes were selected as described in the methods. (C) Left, Venn diagram of the genes upregulated in MUC16-positive cells and the downregulated genes in TET2 KD cells. Right, the table shows the list of 13 overlapping genes. KRT78, MAL, and MYEOV highlighted in red were selected for functional analyses, as described in Figure 6.
Ijms 24 02841 g005
Ijms 24 02841 g006 550
Figure 6. Identification of KRT78, MYEOV, and MAL as epigenetically regulated corneal differentiation genes. (A) Bar graphs represent relative KRT78, MYEOV and MAL mRNA expression in TET2 KD cells (TET2 KD#1: 16.4 ± 18.2%, TET2 ± KD#2: 11.5 ± 15.3% for KRT78, TET2 KD#1: 59.1 ± 39.5%, TET2 ± KD#2: 51.4 ± 45.9% for MYEOV, TET2 KD#1: 16.2 ± 14.5%, TET2 ± KD#2: 23.7 ± 24.3% for MAL; n = 8, * p < 0.05 and **** p < 0.0001). Data were analyzed using a Tukey’s multiple comparisons test. (B) UCSC genome browser depiction of reduced 5hmC enrichment peaks in the KRT78, MYEOV and MAL genomic regions of TET2 KD cells. (C) Bar graphs represent MUC16, TET2, KRT78, MYEOV, and MAL mRNA expression in sorted MUC16-positive and MUC16-negative cells (relative expression in MUC16-negative cells: 3.9 ± 2.8% for MUC16, 19.3 ± 19.6% for TET2, 1.9 ± 4.2% for KRT78, 5.6 ± 5.5% for MYEOV, 23.0 ± 10.8% for MAL; n = 5, *** p < 0.001, **** p < 0.0001). Data were analyzed using a paired t-test. (D) Representative immunostaining images of MUC16 and KRT78 (top), MUC16 and MYEOV (middle), and 5hmC and MAL (bottom) in the central corneal epithelium. Hoechst 33342 was used for the nuclei staining. n = 3. Scale bar, 20 μm. The red frames depict the 5hmC peaks reduced in TET2 KD cells.
Figure 6. Identification of KRT78, MYEOV, and MAL as epigenetically regulated corneal differentiation genes. (A) Bar graphs represent relative KRT78, MYEOV and MAL mRNA expression in TET2 KD cells (TET2 KD#1: 16.4 ± 18.2%, TET2 ± KD#2: 11.5 ± 15.3% for KRT78, TET2 KD#1: 59.1 ± 39.5%, TET2 ± KD#2: 51.4 ± 45.9% for MYEOV, TET2 KD#1: 16.2 ± 14.5%, TET2 ± KD#2: 23.7 ± 24.3% for MAL; n = 8, * p < 0.05 and **** p < 0.0001). Data were analyzed using a Tukey’s multiple comparisons test. (B) UCSC genome browser depiction of reduced 5hmC enrichment peaks in the KRT78, MYEOV and MAL genomic regions of TET2 KD cells. (C) Bar graphs represent MUC16, TET2, KRT78, MYEOV, and MAL mRNA expression in sorted MUC16-positive and MUC16-negative cells (relative expression in MUC16-negative cells: 3.9 ± 2.8% for MUC16, 19.3 ± 19.6% for TET2, 1.9 ± 4.2% for KRT78, 5.6 ± 5.5% for MYEOV, 23.0 ± 10.8% for MAL; n = 5, *** p < 0.001, **** p < 0.0001). Data were analyzed using a paired t-test. (D) Representative immunostaining images of MUC16 and KRT78 (top), MUC16 and MYEOV (middle), and 5hmC and MAL (bottom) in the central corneal epithelium. Hoechst 33342 was used for the nuclei staining. n = 3. Scale bar, 20 μm. The red frames depict the 5hmC peaks reduced in TET2 KD cells.
Ijms 24 02841 g006
Table
Table 1. Downregulated genes with reduced 5hmC levels in TET2 knockdown cells.
Table 1. Downregulated genes with reduced 5hmC levels in TET2 knockdown cells.
Downregulated genes with reduced 5hmC peaks in Exon regions in TET2 KD cells
MYEOVBEST1COLCA1CREBBPKRT34FIBCD1TNNI2PLPP2TLCD1PLCB3
TMC5TIMM44SLC4A2FAM107ACARD10PDXPMIB2TET3SNX8TNFSF14
TEAD4NFATC4KRT23FASNCFDSEMA3BLSP1ATAD3CCCDC88BCAPS
COX4I2MED24ATP2A1TNK2ENO1WNK2MIDNIFI27TXNRD2EMILIN2
CAPN12PLEKHB1DOCK6MUC4UPP1P4HTMSERPINF1PTPRHMSI1NDUFA4L2
ZNF768ATG16L2MALB4GALT5SPTBN2KLF16SLC9A1LEFTY1MBC15orf39
KLK13EPHB6WTIPTMEM205DOT1LQRICH2ISYNA1CHD1HGDRASGRP2
HES6TNFSF13MKNK2REC8MYLPFFBXL19REEP6RNF223MLPHCCK
TBC1D1LTC4SSIGIRRZNF652FUT4PALMH19ARRB2MSI2TF
SLC7A1ABCA7
Downregulated genes with reduced 5hmC peaks in Intron regions in TET2 KD cells
ATP6V1B1AGAP1INF2PALMB4GALT5NCMAPADIPOR2MLPHPPARGC1BWNK2
KCNQ1PPP1R9BCARD10DOT1LSLC6A17BFSP2-AS1ABCA7REEP6SSBP3SMDT1
CORO2ASIGIRRTEAD4NTF3MSI2CCDC57TNK2SLC4A2BGNPRKCB
LYPD5MUC4SNX8FAM20ALMTK3TXNRD2TJP3CSKPHLPP1JDP2
TMC5EMILIN2PKN1ATAD3CASPHD2WTIPLSP1SLC29A2EMP1PRIM1
ZNF652TIMP2MIDNSEC1PTET3HYAL1LYPD2SH2D4ABICDL1SGF29
FAM3D-AS1MKNK2SERPINF1PLPP2LEFTY1PLCB3SLC16A3CAPN12PTPRHMAL
GMPRSPTBN2ENO1SLC9A3R2FAM107BSLC12A5HEXBR3HDM2SLC9A1SLC25A37
ATG16L2NDUFA4L2VWFECI1CREBBPKRT23TNFSF14MUC16MIB2WNT3A
EPHA8SNHG17KRT8FASNS100PCAPNS1SH3GL3ATP2A1MED24MROH6
FBP1RAB26KRT78UPP1APOL6IFI27TLCD1NQO2PTPRDBEST1
SIX1CYBAMOCOSRNF223EEF1A2DGUOK-AS1TBC1D1SLC6A8FAM120AARRB2
MRPL12CRMP1FIBCD1FBXL19P4HTMTMCO4TIMM44PPP2CBCRIP1VEGFA
TMEM205MCRIP2MT1MTMEM164RASGRP2MSI1C15orf39MAP4K1KLK13N4BP3
KLF16VKORC1LGALS9CLEMD1ALMS1TFSLC7A1RASA4BFAM3DNXPH4
MYEOVTET2LRRC56DCTPP1LGALS9ABCA4WNT6SGMS1-AS1PDXPDUSP5
H19IZUMO4
Downregulated genes with reduced 5hmC peaks in Promoter regions in TET2 KD cells
INF2HGDPRR34-AS1B4GALT5EIF4EBP3CYSRT1LSP1KRT78SERPINF1LYPD2
KRT8RAB26TLCD1NQO2ARRB2FAM107ASPTBN2PTPRHCSKNAT14
TJP3SLC4A2LEFTY1PCYT2MLPHTMCO4LGALS9CTMEM205CAPSUPP1
IFI27MALLRRC56MYEOVCCDC88BJDP2UBXN10S100PSGMS1-AS1N4BP3
GMPRCARD10RHBDL1IZUMO4SMDT1
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sasamoto, Y.; Wu, S.; Lee, C.A.A.; Jiang, J.Y.; Ksander, B.R.; Frank, M.H.; Frank, N.Y. Epigenetic Regulation of Corneal Epithelial Differentiation by TET2. Int. J. Mol. Sci. 2023, 24, 2841. https://doi.org/10.3390/ijms24032841

AMA Style

Sasamoto Y, Wu S, Lee CAA, Jiang JY, Ksander BR, Frank MH, Frank NY. Epigenetic Regulation of Corneal Epithelial Differentiation by TET2. International Journal of Molecular Sciences. 2023; 24(3):2841. https://doi.org/10.3390/ijms24032841

Chicago/Turabian Style

Sasamoto, Yuzuru, Siyuan Wu, Catherine A. A. Lee, Jason Y. Jiang, Bruce R. Ksander, Markus H. Frank, and Natasha Y. Frank. 2023. "Epigenetic Regulation of Corneal Epithelial Differentiation by TET2" International Journal of Molecular Sciences 24, no. 3: 2841. https://doi.org/10.3390/ijms24032841

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop